Intrathecal cannabilactone CB2R agonist, AM1710, controls pathological pain and restores basal cytokine levels
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Spinal glial and proinflammatory cytokine actions are strongly implicated in pathological pain. Spinal administration of the anti-inflammatory cytokine interleukin (IL)-10 abolishes pathological pain and suppresses proinflammatory IL-1β and tumor necrosis factor alpha (TNF-α). Drugs that bind the cannabinoid type-2 receptor (CB(2)R) expressed on spinal glia reduce mechanical hypersensitivity. To better understand the CB(2)R-related anti-inflammatory profile of key anatomical nociceptive regions, we assessed mechanical hypersensitivity and protein profiles following intrathecal application of the cannabilactone CB(2)R agonist, AM1710, in 2 animal models; unilateral sciatic nerve chronic constriction injury (CCI), and spinal application of human immunodeficiency virus-1 glycoprotein 120 (gp120), a model of peri-spinal immune activation. In CCI animals, lumbar dorsal spinal cord and corresponding dorsal root ganglia (DRG) were evaluated by immunohistochemistry for expression of IL-10, IL-1β, phosphorylated p38-mitogen-activated-kinase (p-p38MAPK), a pathway associated with proinflammatory cytokine production, glial cell markers, and degradative endocannabinoid enzymes, including monoacylglycerol lipase (MAGL). AM1710 reversed bilateral mechanical hypersensitivity. CCI revealed decreased IL-10 expression in dorsal spinal cord and DRG, while AM1710 resulted in increased IL-10, comparable to controls. Adjacent DRG and spinal sections revealed increased IL-1β, p-p38MAPK, glial markers, and/or MAGL expression, while AM1710 suppressed all but spinal p-p38MAPK and microglial activation. In spinal gp120 animals, AM1710 prevented bilateral mechanical hypersensitivity. For comparison to immunohistochemistry, IL-1β and TNF-α protein quantification from lumbar spinal and DRG homogenates was determined, and revealed increased DRG IL-1β protein levels from gp120, that was robustly prevented by AM1710 pretreatment. Cannabilactone CB(2)R agonists are emerging as anti-inflammatory agents with pain therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Bennett, G. J., & Xie, Y.-K. (1988) · Pain · doi:10.1016/0304-3959(88)90209-6 · Cited by 5,376
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways?
Son, Y., Cheong, Y.-K., Kim, N.-H., Chung, H.-T., Kang, D. G., & Pae, H.-O. (2011) · Journal of Signal Transduction · doi:10.1155/2011/792639 · Cited by 1,219 · cited 3×
“CB2R activation impacts signaling pathways involving cAMP, ERK1/2, JNK, p38-MAPKs, and NO production [12,13,16,17] by several potential mechanisms.”
BackgroundA Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177
Kawasaki, Y., Zhang, L., Cheng, J.-K., & Ji, R.-R. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3338-07.2008 · Cited by 1,162
Structure and function of fatty acid amide hydrolase
McKinney, M. K., & Cravatt, B. F. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133450 · Cited by 680 · cited 3×
“Inhibitors of FAAH and MAGL that result in increased CNS levels of anandamide and 2-AG suppress pathological pain [36,37,42,46].”
BackgroundEljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P. M., Wolf, S., Hoertnagl, H., Raine, C. S., Schneider-Stock, R., Nitsch, R., et al. (2006) · Neuron · doi:10.1016/j.neuron.2005.11.027 · Cited by 445 · cited 2×
“CB2R activation impacts signaling pathways involving cAMP, ERK1/2, JNK, p38-MAPKs, and NO production [12,13,16,17] by several potential mechanisms.”
BackgroundWatkins, L. R., Hutchinson, M. R., Rice, K. C., & Maier, S. F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.002 · Cited by 438 · cited 2×
“characterized to involve activated spinal glia and proinflammatory cytokine activity [95].”
BackgroundGuindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423 · cited 2×
“Activation of CB2Rs lack the known CNS side effects produced by CB1R activation [8,21,71,72,102].”
BackgroundZhang, J., Hoffert, C., Vu, H. K., Groblewski, T., Ahmad, S., & O'Donnell, D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02704.x · Cited by 419 · cited 3×
“CB2R expression has been identified mostly in spinal microglia [8,67,70,71,102].”
Background
Cited by
Glia and pain: Is chronic pain a gliopathy?
Ji, R.-R., Berta, T., & Nedergaard, M. (2013) · Pain · doi:10.1016/j.pain.2013.06.022 · Cited by 1,187
Immune modulation by curcumin: The role of interleukin-10
Mollazadeh, H., Cicero, A. F. G., Blesso, C. N., Pirro, M., Majeed, M., & Sahebkar, A. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1358139 · Cited by 381
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 376
Pertwee, R. G. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0381 · Cited by 347
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Self-citationThe therapeutic potential of interleukin-10 in neuroimmune diseases
Kwilasz, A. J., Grace, P. M., Serbedzija, P., Maier, S. F., & Watkins, L. R. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.020 · Cited by 227
“…blood, sciatic nerve, dorsal root ganglion (DRG), spinal cord and/or cerebrospinal fluid (CSF) tissues are decreased versus healthy controls (Backonja et al., 2008; Franchi et al., 2012; George et al., 2004; Jancalek et al., 2011; Liou et al., 2011; Uceyler et al., 2007; Wilkerson et al., 2012a).”
BackgroundAn overview of the cannabinoid type 2 receptor system and its therapeutic potential
Bie, B., Wu, J., Foss, J. F., & Naguib, M. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000616 · Cited by 206
Deng, L., Guindon, J., Vemuri, V. K., Thakur, G. A., White, F. A., Makriyannis, A., & Hohmann, A. G. (2012) · Molecular Pain · doi:10.1186/1744-8069-8-71 · Cited by 94
Self-citationWilkerson, J. L., Ghosh, S., Mustafa, M., Abdullah, R. A., Niphakis, M. J., Cabrera, R., Maldonado, R. L., Cravatt, B. F., & Lichtman, A. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.015 · Cited by 78
Self-citation
Metadata
- Authors
- Wilkerson, J. L., Gentry, K. R., Dengler, E. C., Wallace, J. A., Kerwin, A. A., Armijo, L. M., Kuhn, M. N., Thakur, G. A., Makriyannis, A., & Milligan, E. D.
- Venue
- Pain
- Published
- 2012-05
- Volume
- 153
- Issue
- 5
- Pages
- 1091-1106
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2085052329
- Cited by
- 100
- References
- 18
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.